IVA logo

IVA
Inventiva - ADR

557
Mkt Cap
$821.27M
Volume
3,696.00
52W High
$7.98
52W Low
$2.11
PE Ratio
-1.05
IVA Fundamentals
Price
$4.30
Prev Close
$3.88
Open
$4.01
50D MA
$5.03
Beta
0.64
Avg. Volume
330,164.04
EPS (Annual)
-$3.33
P/B
-54.54
Rev/Employee
$83,608.34
Loading...
Loading...
News
all
press releases
Inventiva (NASDAQ:IVA) Trading Up 11.1% - Should You Buy?
Inventiva (NASDAQ:IVA) Trading 11.1% Higher - Should You Buy...
MarketBeat·2d ago
News Placeholder
More News
News Placeholder
Inventiva (NASDAQ:IVA) Price Target Lowered to $11.00 at Guggenheim
Guggenheim reduced their target price on Inventiva from $13.00 to $11.00 and set a "buy" rating on the stock in a report on Tuesday...
MarketBeat·5d ago
News Placeholder
Inventiva (NASDAQ:IVA) Shares Gap Up - Time to Buy?
Inventiva (NASDAQ:IVA) Shares Gap Up - Here's Why...
MarketBeat·6d ago
News Placeholder
Inventiva (NASDAQ:IVA) Sees Unusually-High Trading Volume - Here's Why
Inventiva (NASDAQ:IVA) Sees Strong Trading Volume - Here's Why...
MarketBeat·10d ago
News Placeholder
Inventiva (NASDAQ:IVA) Trading Down 5.5% - Here's Why
Inventiva (NASDAQ:IVA) Shares Down 5.5% - Should You Sell...
MarketBeat·13d ago
News Placeholder
Here's Why Inventiva (IVA) Is a Great 'Buy the Bottom' Stock Now
Inventiva (IVA) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Zacks·2mo ago
News Placeholder
How Much Upside is Left in Inventiva (IVA)? Wall Street Analysts Think 100.79%
The mean of analysts' price targets for Inventiva (IVA) points to a 100.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks·3mo ago
News Placeholder
Inventiva (IVA) Upgraded to Buy: What Does It Mean for the Stock?
Zacks·6mo ago
News Placeholder
Why Is Fatty-Liver Drug Developer Inventiva Stock Trading Higher On Monday?
Inventiva secures 94.1M in financing, potentially reaching 348M, to fund the Phase 3 NATiV3 trial for lanifibranor in NASH. Leadership changes include new chairman and director appointments. read...
Benzinga·1y ago
News Placeholder
Inventiva Advances Lanifibranor Trial with Promising Data
Inventiva (IVA) has released an update. Inventiva reports strong progress in its NATiV3 Phase III clinical trial for lanifibranor, with over 80% en...
TipRanks Financial Blog·1y ago

Latest IVA News

View

Advertisement|Remove ads.

Advertisement|Remove ads.